Endocrine Abstracts

Introduction: In chronic diseases a good psychological and behavioral adaptation is essential. Concerning diabetes the Insulin Delivery System (IDS) adopted tend to be an important factor of adaptation, global satisfaction and, above all, quality of life (QoL).

Objectives: To analyze the QoL and IDS satisfaction and its relationship with psychopathological symptomatology in patients on continuous subcutaneous insulin infusion (CSII) therapy.

Patients and methods: We gather a convenience sample of 42 type 1 (DM1) patients, with a mean age of 28.4±11.5 years, 61.9% female and with a mean IDS time of usage of 5.6±2 years. We applied the following questionnaires: the Audit of Diabetes Dependent Quality of Life (ADDQoL), o Insulin Delivery System Rating Questionnaire (IDSRQ) e o Brief Symptom Inventory (BSI).

Results: Relatively to QoL, in this sample, the mean values were −1.68±1.37 (results go from −9 to 9). We did not find any relevant psychopathological symptomatology in general in the BSI questionnaire (GSI =0.10±0.09). Regarding blood glucose monitoring (BGM), 55.3% of patients perform 4–6 blood checks daily and 39.5% more than six times daily. 30% of patients carry out BMG a little more than they would like and 22.5% a lot more than they would like. We noticed a significant statistical correlation between QoL and the level of satisfaction with BGM needed (r=−0.50; P=0.001) and also with psychopathological symptomatology (r=−0.53; P=0.001).

Conclusions: Results in this study shows that the chosen IDS has a vital impact in psychopathological symptomatology and in the levels of QoL that patients reveal. This data allow us to conclude that the minor constraints that this IDS has due to its utilization does not contribute negatively to CSII perception, moreover when it is compared with multiple daily dosage.